What Do Analysts Think About Elevance Health (ELV)?

Core Insights - Elevance Health, Inc. (NYSE:ELV) is currently viewed as one of the best affordable healthcare stocks to buy, despite a recent downgrade by Deutsche Bank from Buy to Hold, with a price target reduction from $332 to $320 [1] - Following disappointing Q2 earnings, Elevance Health's stock dropped by 18.66%, although BofA raised its price target from $370 to $385 while maintaining a Neutral rating, indicating higher peer multiples [2] Management and Governance - Elevance Health's board appointed Amy Schulman as an independent director, effective January 12, 2026, who will serve on the Audit and Finance Committees, bringing expertise in regulatory strategy and healthcare innovation [3] - The appointment of Schulman is part of Elevance Health's strategy for board refreshment, aiming for independent, diverse, and future-focused leadership aligned with stakeholder priorities [4] Product and Service Expansion - Elevance Health announced the expansion of its Virtual Assistant, a digital tool designed to help members navigate their benefits and access care, available through the Sydney Health app and affiliated health plan websites [5] Business Segments - Elevance Health operates through several segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other, with the Health Benefits segment providing a range of health plans and services, and CarelonRx managing pharmacy services [6]